{"id":"W4379259102","doi":"10.1158/2159-8290.cd-23-0153","title":"The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study","year":2023,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Regional Cancer Foundation; Ottawa Hospital","funders":"Daiichi Sankyo Europe; National Center for Advancing Translational Sciences; Springworks Therapeutics; National Cancer Institute; Regeneron Pharmaceuticals","keywords":"Neutropenia; Vomiting; Nausea; Antagonist; Adverse effect; Medicine; Internal medicine; Liposarcoma; Phases of clinical research; Response Evaluation Criteria in Solid Tumors; Pharmacokinetics; Gastroenterology; Pharmacology; Oncology; Chemotherapy; Sarcoma; Pathology; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004100103,0.0002850815,0.0006116993,0.0002866418,0.0001323141,0.00005174613,0.0001806027,0.0000525289,0.00001506932],"category_scores_gemma":[0.0002186319,0.0001907866,0.00008985698,0.001373411,0.0001635183,0.0003127469,0.00007530172,0.0003217783,0.000007146345],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005638586,"about_ca_system_score_gemma":0.0004868413,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001324617,"about_ca_topic_score_gemma":0.01419786,"domain_scores_codex":[0.9973336,0.0001103686,0.0008871419,0.0005576285,0.0006333458,0.0004778466],"domain_scores_gemma":[0.998574,0.0001756677,0.0003817753,0.0006392575,0.0001356099,0.000093724],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2106258,0.02426126,0.5748322,0.002391784,0.002378877,0.003444748,0.02260181,0.07379682,0.01784967,0.0002045204,0.006028313,0.06158414],"study_design_scores_gemma":[0.1272969,0.01014852,0.8431436,0.003506206,0.0004984681,0.000007664687,0.00389891,0.002058357,0.00747392,0.0001122309,0.001130332,0.0007248208],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9959214,0.0003152498,0.00004211265,0.0002976704,0.0002407332,0.002619288,0.0003573186,0.00005217747,0.000154093],"genre_scores_gemma":[0.9984192,0.0001747418,0.00002854066,0.00006201657,0.00005297256,0.0004308486,0.000272288,0.00006424877,0.0004951865],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2683114,"threshold_uncertainty_score":0.7922738,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02060908733489273,"score_gpt":0.3379968942313015,"score_spread":0.3173878068964088,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}